This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

AOP: 638

Title

A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
MPs & Cd induced inflammation-to-cancer transition in liver
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v2.8

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool

Authors

The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

李宇涵,牟为

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help

Contributors

Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Li Yuhan
  • Wei Mu

Coaches

This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
This AOP was last modified on March 29, 2026 02:53

Revision dates for related pages

Page Revision Date/Time
COL3A1 Signaling Pathway March 25, 2026 08:17
Release, Cytokine September 16, 2017 10:14
Increase, Reactive oxygen species June 12, 2025 01:27
modulation, Extracellular Matrix Composition September 16, 2017 10:17
Necrosis February 07, 2017 13:22
Pyroptosis January 19, 2022 05:03
Apoptosis May 31, 2025 08:50
Activation of inflammation pathway May 31, 2022 02:47
Increase, Cell Proliferation December 10, 2024 15:01
Increase, Liver fibrosis February 11, 2026 05:35
Liver Cancer June 19, 2021 15:00
COL3A1 Signaling Pathway leads to modulation, Extracellular Matrix Composition March 25, 2026 08:36
modulation, Extracellular Matrix Composition leads to Increase, Cell Proliferation March 25, 2026 08:36
Increase, Cell Proliferation leads to Liver Cancer March 25, 2026 08:36
Release, Cytokine leads to Necrosis March 25, 2026 08:39
Release, Cytokine leads to Apoptosis March 25, 2026 08:39
Release, Cytokine leads to Activation, inflammation pathway March 25, 2026 08:41
Necrosis leads to Activation, inflammation pathway March 25, 2026 08:41
Pyroptosis leads to Activation, inflammation pathway March 25, 2026 08:42
Activation, inflammation pathway leads to Increase, Liver fibrosis March 25, 2026 08:49
modulation, Extracellular Matrix Composition leads to Increase, Liver fibrosis March 25, 2026 08:51
Increase, ROS leads to Pyroptosis March 25, 2026 08:51
Increase, ROS leads to Apoptosis April 11, 2024 15:22
Apoptosis leads to Increase, Liver fibrosis March 25, 2026 08:52
Apoptosis leads to Liver Cancer March 25, 2026 08:52
Cadmium October 25, 2017 08:33
Nanoparticles and Micrometer Particles February 04, 2022 13:43

Abstract

A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

This Adverse Outcome Pathway (AOP) describes the pathological transformation of the liver from non-alcoholic fatty liver disease (NAFLD) to cirrhosis and ultimately to hepatocellular carcinoma under the combined exposure of microplastics and cadmium. The Molecular Initiating Events (MIEs) are characterized by COL3A1 signaling pathway, ROS generation, and cytokine aggregation. These triggers lead to a series of Key Events (KEs), including alterations in ECM organization, increased cell proliferation, the occurrence of three distinct types of cell death, and chronic inflammation. This biological cascade eventually results in two primary Adverse Outcomes (AOs): liver cancer and hepatic fibrosis. By delineating these relationships, this AOP provides a novel scientific perspective on the hepatotoxicity induced by the interaction between microplastics and heavy metals.

AOP Development Strategy

Context

Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

Microplastics (MPs), fragments and particles ≤5 mm in diameter, persistently accumulate in the environment and have been detected in various human tissues and organs, including infant placental tissues. Once ingested via food or water, MPs can deposit in the liver, leading to significant tissue injury. Polystyrene microplastics (PS-MPs), widely used in disposable food packaging, are frequently employed as models to study these environmental effects. Beyond their inherent toxicity, PS-MPs can enter the human body and serve as carriers for other environmental pollutants. Among these co-exposed contaminants, heavy metals such as cadmium (Cd) are of particular concern due to their high carcinogenicity and shared exposure pathways with MPs through aquatic products, agricultural goods, and water resources.

Both MPs and Cd are ubiquitous pollutants that accumulate in the liver through food chain transfer and biomagnification, with absorbed dietary Cd exhibiting an exceptionally long biological half-life. As a primary target organ for both stressors, the liver undergoes amplified toxicological outcomes during co-exposure. Individual exposure to either Cd or MPs is known to induce oxidative stress, provoke inflammatory cascades, initiate apoptotic pathways, and disrupt hepatic metabolic homeostasis. When combined, these pollutants may result in a synergistic effect that accelerates pathological progression.

External stimuli and a sustained inflammatory microenvironment are key drivers in the development of liver cancer. This tumorigenic process is highly heterogeneous and involves a continuum of metabolic disorders, where Non-Alcoholic Fatty Liver Disease (NAFLD) serves as a significant precursor to liver fibrosis and eventual malignancy. Research indicates that long-term Cd exposure can drive the entire disease progression from NAFLD to fibrosis and liver cancer through the activation of endogenous reactive oxygen species (ROS). Furthermore, higher concentrations of plastic particles have been detected in cirrhotic liver tissues compared to healthy ones, and joint exposure to PS-MPs and Cd has been shown to promote fibrosis by regulating oxidative stress and cell death. Given that the transformation from inflammation to cancer involves complex molecular cascades and extended periods, this AOP is developed as a predictive tool to construct a hazard assessment framework for the synergistic hepatotoxicity of microplastics and heavy metals.

Strategy

Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

Initial data on chemicals, genes, and disease interactions were collected from the CTD and GeneCards databases, focusing on the progression from NAFLD to liver cirrhosis and liver cancer. These target genes were categorized into three developmental stages and analyzed using GO and KEGG pathways, while protein-protein interaction networks were constructed to establish the molecular foundation. Following this preliminary predictive modeling, in vivo and in vitro experiments were conducted to provide empirical evidence for the proposed biological transitions.

Existing knowledge from the AOP-Wiki regarding cadmium and microplastics was further integrated to build a baseline network of pollutant-induced liver injury. By synthesizing enrichment analysis, interaction networks, and experimental results, the upstream and downstream relationships of key genes and pathways were identified and weighted. This approach, combining computational prediction and experimental verification, led to the final construction of the AOP mapping the progression from NAFLD through liver cirrhosis to liver cancer under combined exposure.

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help

Events:

Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
MIE 2414 COL3A1 Signaling Pathway COL3A1 Signaling Pathway
MIE 87 Release, Cytokine Release, Cytokine
MIE 1115 Increase, Reactive oxygen species Increase, ROS
KE 1195 modulation, Extracellular Matrix Composition modulation, Extracellular Matrix Composition
KE 1263 Necrosis Necrosis
KE 1967 Pyroptosis Pyroptosis
KE 1262 Apoptosis Apoptosis
KE 2009 Activation of inflammation pathway Activation, inflammation pathway
KE 870 Increase, Cell Proliferation Increase, Cell Proliferation
AO 344 Increase, Liver fibrosis Increase, Liver fibrosis
AO 1395 Liver Cancer Liver Cancer

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help
Life stage Evidence
Not Otherwise Specified

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help
Term Scientific Term Evidence Link
mammals mammals Moderate NCBI

Sex Applicability

The sex for which the AOP is known to be applicable. More help
Sex Evidence
Unspecific

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

By integrating bioinformatic analysis and findings from in vivo and in vitro experiments with established AOPs of pollutant-induced hepatic injury, a comprehensive AOP network is constructed to delineate the "inflammation-to-cancer" disease progression under the combined exposure to MPs and Cd.

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help

Molecular associations were derived from CTD and GeneCards to reflect environmental impacts on human health. Empirical validation was conducted in vivo using four-week-old male BALB/c mice, and in vitro using murine AML12 hepatocytes and human HepG2 liver cancer cells.

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

MIEs: COL3A1 signaling pathway; Release, cytokine (MIE: 87); and Increased, ROS (MIE: 1115) The essentiality of these MIEs is supported by the fact that increased reactive oxygen species and cytokine release govern the entire disease trajectory, acting as the indispensable molecular triggers for downstream pathological remodelling.

KE1: Modulation, Extracellular Matrix Composition (KE ID: 1195) As a structural protein essential to the ECM, COL3A1 expression is a requirement for ECM remodeling. The modulation of ECM composition is an essential functional transition leading to the adverse outcome of liver fibrosis.

KE2-4: Pyroptosis (KE ID: 1967); Necrosis (KE ID: 1263); and Apoptosis (KE ID: 1262) The occurrence of multiple programmed cell death pathways is critical for the "inflammation-to-cancer" transformation. These KEs are essential, as they serve as the bridge linking early oxidative stress and cytokine signaling to chronic tissue damage.

KE5: Activation of Inflammation (KE ID: 2009) Inflammatory activation is a necessary driver of the robust immune response and subsequent tissue damage. This KE is mediated by various forms of cell death and cytokines that occur across all disease stages.

KE6: Increase, Cell Proliferation (KE ID: 870) Cell proliferation is a fundamental requirement for tumorigenesis following chronic injury. It represents the necessary final step linking chronic inflammatory damage and ECM modulation to the development of liver cancer.

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

MIEs to Cell Death and Cytokine Release Research indicates that combined exposure to microplastics and Cd significantly increases ROS levels and disrupts mitochondrial homeostasis, directly triggering the release of pro-inflammatory cytokines and initiating programmed cell death pathways.

MIEs to KE1 (ECM Modulation) PPI analysis reveals that COL3A1 signaling is a central node impacting both "inflammatory/NAFLD" and "liver cirrhosis" phases. In co-exposure models, COL3A1 is consistently enriched in ECM-related pathways, and the elevation of integrin ITGB5 further confirms the role of cell-ECM interactions.

KE2-4 (Cell Death) to KE5 (Inflammation) Analysis shows that necrosis-associated genes (BIRC3, RIPK3) and pyroptosis markers (CASP8) are enriched during disease progression. Necrosis and pyroptosis lead to cellular rupture and the release of intracellular contents, which activate the strong inflammatory response observed in animal models.

KE1 & KE5 to KE6 (Cell Proliferation) Bioinformatic evidence demonstrates that cell proliferation pathways are activated following ECM modulation and NF-κB-mediated inflammation. The ECM regulates cellular activities, while persistent inflammation stimulates the growth of initiated cells.

Pathway to Adverse Outcomes The integrated relationships among target genes and pathways facilitate the transition from NAFLD to liver fibrosis (defined by excessive ECM deposition) and ultimately to liver cancer (induced by sustained cell proliferation and inflammation).

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help
Modulating Factor (MF) Influence or Outcome KER(s) involved
     

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help

References

List of the literature that was cited for this AOP. More help

[1] Li Y, Jian Y, Zhou J, Zhang M, Zhou Y, Ge Y, Wang H, Mu W. Molecular regulatory networks of microplastics and cadmium mediated hepatotoxicity from NAFLD to tumorigenesis via integrated approaches. Ecotoxicol Environ Saf. 2025 Jul 15;300:118431. doi: 10.1016/j.ecoenv.2025.118431.

[2] Wang, P., Chen, H., Kopittke, P. M., & Zhao, F.-J. (2019). Cadmium contamination in agricultural soils of China and the impact on food safety. Environmental Pollution, 249, 1038-1048. doi:10.1016/j.envpol.2019.03.063

[3] Wang, Y., Nan, X., Sun, H., Shi, Y., Miao, J., Li, Y., . . . Liu, B. (2024). From insects to mammals! Tissue accumulation and transgenerational transfer of micro/nano-plastics through the food chain. Journal of Hazardous Materials, 480. doi:10.1016/j.jhazmat.2024.136424

[4] Haouem, S., & El Hani, A. (2013). Effect of Cadmium on Lipid Peroxidation and on Some Antioxidants in the Liver, Kidneys and Testes of Rats Given Diet Containing Cadmium-polluted Radish Bulbs. Journal of Toxicologic Pathology, 26(4), 359-364. doi:10.1293/tox.2013-0025

[5] Horvatits, T., Tamminga, M., Liu, B., Sebode, M., Carambia, A., Fischer, L., . . . Fischer, E. K. (2022). Microplastics detected in cirrhotic liver tissue. eBioMedicine, 82. doi:10.1016/j.ebiom.2022.104147

[6] Lan, Y., Hu, L., Feng, X., Wang, M., Yuan, H., & Xu, H. (2024). Synergistic effect of PS-MPs and Cd on male reproductive toxicity: Ferroptosis via Keap1-Nrf2 pathway. Journal of Hazardous Materials, 461. doi:10.1016/j.jhazmat.2023.132584

[7] Li, J., Yin, K., Hou, L., Zhang, Y., Lu, H., Ma, C., & Xing, M. (2023). Polystyrene microplastics mediate inflammatory responses in the chicken thymus by Nrf2/NF-κB pathway and trigger autophagy and apoptosis. Environmental Toxicology and Pharmacology, 100. doi:10.1016/j.etap.2023.104136

[8] Sun, X.-H., Lv, M.-W., Zhao, Y.-X., Zhang, H., Ullah Saleem, M. A., Zhao, Y., & Li, J.-L. (2022). Nano-Selenium Antagonized Cadmium-Induced Liver Fibrosis in Chicken. Journal of Agricultural and Food Chemistry, 71(1), 846-856. doi:10.1021/acs.jafc.2c06562

[9] Sheng, S., Han, N., Wei, Y., Wang, J., Han, W., Xing, B., . . . Zhang, W. (2023). Liver Injury Induced by Exposure to Polystyrene Microplastics Alone or in Combination with Cadmium in Mice Is Mediated by Oxidative Stress and Apoptosis. Biological Trace Element Research, 202(5), 2170-2183. doi:10.1007/s12011-023-03835-5

[10] Wei, W., Yang, Q., Xiang, D., Chen, X., Wen, Z., Wang, X., . . . Xu, J. (2023). Combined impacts of microplastics and cadmium on the liver function, immune response, and intestinal microbiota of crucian carp (Carassius carassius). Ecotoxicology and Environmental Safety, 261. doi:10.1016/j.ecoenv.2023.115104

[11] Cichoz-Lach, H., & Michalak, A. (2014). Oxidative stress as a crucial factor in liver diseases. World Journal of Gastroenterology, 20(25), 8082-8091. doi:10.3748/wjg.v20.i25.8082

[12] Fontes-Cal, T. C. M., Mattos, R. T., Medeiros, N. I., Pinto, B. F., Belchior-Bezerra, M., Roque-Souza, B., . . . Gomes, J. A. S. (2021). Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Frontiers in Immunology, 12. doi:10.3389/fimmu.2021.708959

[13] Tang, D., Kang, R., Berghe, T. V., Vandenabeele, P., & Kroemer, G. (2019). The molecular machinery of regulated cell death. Cell Research, 29(5), 347-364. doi:10.1038/s41422-019-0164-5

[14] Wu, Y., Zhang, J., Yu, S., Li, Y., Zhu, J., Zhang, K., & Zhang, R. (2022). Cell pyroptosis in health and inflammatory diseases. Cell Death Discovery, 8(1). doi:10.1038/s41420-022-00998-3